Abstract #1530
Phospholipidosis affects Hepatobiliary Function as assessed by Gadoxetate DCE-MRI
Stephen Lenhard 1 , Debra Paul 2 , Mally Lev 3 , Lindsey Webster 4 , Christopher Goulbourne 5 , Richard Peterson 5 , Richard Miller 6 , and Beat Jucker 1
1
Pre-clinical and Translational Imaging,
GlaxoSmithKline, King of Prussia, Pennsylvania, United
States,
2
LAS,
GlaxoSmithKline, King of Prussia, Pennsylvania, United
States,
3
DMPK,
GlaxoSmithKline, King of Prussia, Pennsylvania, United
States,
4
DMPK,
GlaxoSmithKline, Research Triangle Park, North Carolina,
United States,
5
Safety
Assesment, GlaxoSmithKline, Research Triangle Park,
North Carolina, United States,
6
LAS,
GlaxoSmithKline, Research Triangle Park, North Carolina,
United States
Phospholipidosis (PLD) is a generalized condition in
humans and animals characterized by an intracellular
accumulation of phospholipids. Using a clinically
available liver specific MRI contrast agent
(Eovist;Gadoxetate) we performed hepatobiliary Dynamic
Contrast Enhanced MRI (DCE-MRI) to determine if
Gadoxetate kinetic changes could be detected with a
known inducer of hepatic PLD (Amiodarone). Amiodarone
induced a significant decrease in Gadoxetate washout
rate which returned to baseline levels after the 2 week
washout of Amiodarone. Gadoxetate DCE MRI of liver
function may be a useful technique to assess hepatic
functional consequences of PLD for compounds found to
induce PLD.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
